Watchtower Free coverage check

Zepbound (tirzepatide)

A preview of the What changed report: everything new on a drug in the past 90 days, or since your last Watchtower report, with what it was before and what it is now. Order it once for $1,000, or get it every week or month as part of monitoring.

Sponsor
Eli Lilly and Company
Window
Jul 26 to Oct 24, 2026 (90 days)
Same molecule as
Mounjaro
Order a What changed report, $1,000 How monitoring works

In the past 90 days

Brand and molecule

7

Significant changes across trials, FDA, patents, and filings

Molecule

41

New tirzepatide studies registered

Molecule

63

SEC filings from 30 companies naming tirzepatide or Zepbound

Brand changes apply to Zepbound itself.

Molecule changes apply to every brand of tirzepatide, including Mounjaro.

What changed

Three of the seven significant changes, newest first.

  1. New competitor trialMolecule

    Roche will test its drug head to head against tirzepatide

    ENI-SPIRE-2, a Phase 3 trial registered by Roche, compares enicepatide with tirzepatide in 948 adults with type 2 diabetes. Its primary completion date is April 2029.

    Source: NCT07889648 on ClinicalTrials.gov

  2. Label updateBrand

    A major label change on diabetic eye complications

    FDA approved an efficacy supplement on Aug 26. The label published Sep 2 lists section 5.8, Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Mellitus, as a major change dated August 2026. The indications did not change.

    Before
    Label of May 6, 2026 (version 38)
    After
    Label of Sep 2, 2026 (version 40), with the section 5.8 change

    Sources: Zepbound label on DailyMed, Drugs@FDA

  3. Generic challengeBrand

    Generic makers now challenge every KwikPen strength

    Paragraph IV certifications were filed against the 20, 30, 40, and 50 mg KwikPen strengths, adding to the June filing against the 10 and 60 mg strengths.

    Before
    Challenges against 2 of 6 KwikPen strengths
    After
    Challenges against all 6 KwikPen strengths

    Source: FDA Paragraph IV certification list

4 more changes in the full report, including a new Lilly combination program built on tirzepatide, a new pediatric trial, a sponsor filing, and an FDA step toward generic competition, plus what the August efficacy supplement covered.

What didn’t change

Knowing what held steady matters as much as what moved.

  • No new patents listed. The latest Orange Book patent submission for Zepbound is dated Jun 5, 2026.
  • Indications unchanged. Zepbound remains approved for chronic weight management and for obstructive sleep apnea in adults with obesity.
  • Exclusivity dates unchanged. The first, new-product exclusivity still ends Nov 8, 2026.

Coming up

Dates on the record for the next window.

  1. Brand

    New-product exclusivity ends.

  2. Molecule

    TRIUMPH-5, Lilly’s Phase 3 comparing retatrutide with tirzepatide, reaches its primary completion date.

In the full report: every dated event in the next 90 days, including FDA study deadlines and expected trial results.

Get this for any drug, once or on a schedule.

Order a What changed report covering the past 90 days, or get one every week or month for each drug you watch, with alerts for urgent changes in between.

Order a What changed report, $1,000 Set up monitoring

This sample was assembled from public records for illustration. It is not a customer deliverable.